期刊文献+

瑞芬太尼复合丙泊酚静脉全麻用于声带息肉摘除术的临床观察

Observation of General Anesthesia with Infusion of Remifentanil-propoful in Vocal Cord Polyp Extirpation
原文传递
导出
摘要 目的探讨瑞芬太尼复合丙泊酚静脉全麻用于声带息肉摘除术的临床应用价值。方法选择ASAⅠ~Ⅱ级,择期行声带息肉手术患者60例,随机分为瑞芬太尼复合丙泊酚组(R组,n=30)和芬太尼组(F组,n=30),R组采用咪达唑仑-维库溴铵-瑞芬太尼-丙泊酚诱导和维持麻醉,F组采用咪达唑仑-维库溴铵-芬太尼-丙泊酚诱导和异氟醚吸入维持麻醉,观察2组麻醉诱导和维持期血流动力学变化,术毕停药后患者自主呼吸恢复时间、呼之睁眼时间、拔管时间、定向力恢复时间和离开恢复室时间。结果R组麻醉中循环波动小,患者自主呼吸恢复时间、呼之睁眼时间、拔管时间和离开恢复室时间较F组快。结论瑞芬太尼复合丙泊酚全麻可安全有效地用于声带息肉手术,有较高的临床价值。 Objective To study the safe and effective anesthesia methods in polyp of vocal cord extirpation. Methods Total 60 patients (ASA Ⅰ - Ⅱ ) undergoing vocal cord polyp extirpation were randomly divided into two groups (n = 30). Remifentanil group were given anesthetic induction and maintenance with midazolam -vecuronium -remifentanil -propofol;while Group F enfanil were given anesthetic induction with midazolam - vecuronium - fentanil - propofol and maintenance with isoflurance. The hemodynamics during induction of anesthesia and maintenance anesthesia, and time for stoping administration of anesthethetic untill full spontaneous respiration, eye opening, tracheal extubation,orientation and discharging from the postanesthetic care unit (PACU) were compared. Results Anesthesia by remifentanil produces less circulatory fluctuation, and less time for full spontaneous respiration, eye opening, tracheal extubation, orientation and discharging from the PACU than group F. Conclusion Anesthesia with midazolam- vecuronium -remifentanil- propofol can be used safely and effectively in vocal cord polyp extirpation.
作者 邢书军
出处 《医药论坛杂志》 2009年第11期47-48,51,共3页 Journal of Medical Forum
关键词 声带息肉 瑞芬太尼 芬太尼 丙泊酚 Polyp of vocal cord Remifentanil Fentanil Propoful
  • 相关文献

参考文献6

二级参考文献28

  • 1夏延德.维库溴铵持续滴注与间断静注临床效果的比较[J].河南外科学杂志,2004,10(6):31-32. 被引量:2
  • 2李扬,熊利泽,杨博,陈绍洋,王庆德.维库溴铵在神经外科麻醉中的应用[J].中华神经外科疾病研究杂志,2005,4(4):353-356. 被引量:9
  • 3Harrison G.Dosage of dantrolene:"empiric"please! Anaesth Intensive Care,2003,31:122.
  • 4McCarthy EJ.Malignant hyperthermia:pathophysiology,clinical presentation,and treatment.AACN Clin Issues,2004,15:231-237.
  • 5Larach MG,Localio AR,Allen GC,et al.A clinical grading scale to predict malignant hyperthermia susceptibility.Anesthesiology,1994,80:771-779.
  • 6Hopkins PM.Malignant hyperthermia:advances in clinical management and diagnosis.Br J Anaesth,2000,85:118-128.
  • 7Islander G,Twetman ER.Comparison between the European and North American protocols for diagnosis of malignant hyperthermia susceptibility in humans.Anesth Analg,1999,88:1155-1160.
  • 8Bendahan D,Guis S,Monnier N,et al.Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine:a comparative investigation in malignant hyperthermia.Acta Anaesthesiol Scand,2004,8:1019-1027.
  • 9Bendahan D,Kozak Ribbens G,Rodet L,et al.31 Phosphorus magnetic resonance spectroscopy characterization of musclular metabolic anomalies in patients with malignant hyperthermia:application to diagnosis.Anesthesiology,1998,88:96-107.
  • 10Rosenbe rg H,Antognini JF,Muldoon S.Testing for malignant hyperthermia.Anesthesiology,2002,96:232-237.

共引文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部